Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II ensartinib study in RDAA-positive non-small cell lung cancer
ChiCTR2100054794Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ensartinib in non-small cell lung cancer (NSCLC), sponsored by West China Hospital of Sichuan University. Primary endpoint: objective response rate. Started Dec 2021; status: recruiting.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100054794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054794.